1620843-80-2

Upstream product

• 41302-34-5 2-(methoxycarbonyl)cyclohexanone 
• 35042-48-9 2,4-Dihydroxy-5,6,7,8-tetrahydroquinazoline 
• 1127-85-1 2,4-dichloro-5,6,7,8-tetrahydro-quinazoline 
• 578-54-1 ortho-ethylaniline 
• 20191-74-6 2-ethyl-5-nitroaniline 
• 6494-19-5 3-methyl-6-nitro-1H-indazole 
• 444731-73-1 2,3?dimethyl?6?nitro?2H?indazole 
• 444731-72-0 2,3-dimethyl-6-amino-2H-indazole 
• 1620059-33-7 C₁₇H₁₈ClN₅ 
• 6973-09-7 5-amino-2-methylbenzenesulfonamide 
• 1620059-36-0 C₁₈H₂₀ClN₅ 

Relevant academic research and scientific papers

Discovery and synthesis of N2,N4-substitued- cycloalkyl[d]pyrimidine-2,4-diamine analogs: The first examples of small-molecular FGFR-1 activator

A series of novel, cycloalkyl-modified pazopanib analogs 2 and 3 were designed and synthesized. Their kinase modulatory effects on FGFR-1, VEGFR-2, PDGFR-β, and c-KIT were evaluated by the caliper mobility shift assay. Introduction of cycloalkyl into the pyrimidine linker of pazopanib almost abolished the four kinases inhibitory potency of compounds 2 and 3, but surprisingly, resulted in good activation effects on FGFR-1. Compounds 3d and 3g showed double-digit, nanomolar, selective activation effects on FGFR-1, and could be classified as first-generation small molecular activators of FGFR-1 kinase.